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PHYSIOPATHOLOGICAL IMPLICATIONS OF 7TM RECEPTORS 
 
 
Abstract: Seven-transmembrane (7TM) receptors are one of the most important 
proteins involved in perception of extracellular stimuli and regulation of variety of 
intracellular signaling pathways. Divergence of receptor types, their ligands and 
signaling pathways makes 7TM receptors important factors in pathology of many 
diseases. This review focused on the main diseases in which involvement of 7TM 
receptors was established e.g., retinitis pigmentosa, severe obesity, and dwarfism. 
Recent findings of aberrant expression of 7TM receptors in development of cancer 
were also summarized. 
Key words: Seven-transmembrane receptors, G protein coupled receptors, 
pathology, cancer 
 
1. 7TM RECEPTORS AS UNIVERSAL SIGNAL MEDIATORS 
During evolution an extremely diverse family of heptahelical receptor 
proteins emerged. These proteins are called seven-transmembrane receptors 
(7TMRs) or G-protein coupled receptors (GPCRs) due to the fact of signal 
transmission via heterotrimeric G-proteins. The superfamily of 7TM receptors is the 
largest class of cell membrane receptor found in metazoans. The completion of the 
human genome project revealed over 800 genes encoding 7TM receptors 
(LAGERSTROM, SCHIOTH 2008). In view of existence of alternative splice variants 
and editing isoforms of 7TM receptors (CADET et al. 2003; HIRASAWA et al. 1995; 
NELSON, CHALLISS 2007) it is anticipated that true number of functional receptors is 
DOI: 10.2478/v10107-009-0005-2 
7TM receptors and diseases 34
much higher. Sequence of these receptors is highly variable and the only homology 
between all 7TM receptors is the presence of seven α-helical transmembrane 
segments joined by intra- and extracellular loops with N-terminal chain located in 
the extracellular space and C-terminal chain located in cytoplasm. 7TM receptors 
react in response to a varied range of stimuli e.g., light, ions, peptides, lipids, and 
odorants. Upon ligand binding 7TM receptors constrain conformational change in α 
subunit of trimeric G-protein complex. This leads to exchange of GDP molecule for 
GTP and dissociation of G-protein and activation of subsequent intracellular 
responses (BOURNE et al. 1991). 
Biological significance of 7TM receptors was consolidated after reports 
showing that heterotrimeric G-proteins are common, although not exclusive, 
mediators of cellular response after activation of these molecules (PIERCE et al. 
2001; PIERCE et al. 2002). Unusual diversity among 7TM receptors allow them to 
play an important role in wide spectrum of biological processes ranging from 
neurotransmission and hormonal control to perception of taste, smell, light and pain. 
Divergence of stimuli and rich pattern of intracellular signaling pathways 
governed by 7TM receptors makes this group of proteins undoubtedly prone to be 
involved in many pathological processes. In most cases mutation will exhibit as 
gain/loss of function phenotype of 7TM receptor. As a result of inherited mutations 
aberrant receptor will be present in every cell expressing particular gene while in 
somatic mutations even in the case of ubiquitous gene the expression of mutated 
gene will be limited to the cells derived from the progenitor of mutation (SPIEGEL 
1997).  
Mutations in nearly every part of the receptor may cause improper protein 
expression, folding, endoplasmic reticulum retention, or inability to interact with 
other proteins of the signalosome. Such abnormalities will exhibit loss of function 
phenotype and its presence will lead to ligand resistance. Mutations which lead to 
loss of function mutations are usually recessive and unveil their presence in 
homozygotes. Gain of function mutations will in most cases cause constitutive 
activation of the receptors and in case of hormonal signaling cause endocrine 
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hyperfunction. Since such mutations are dominant, heterozygotes are developing 
symptoms of the disease (SPIEGEL 2000).  
At present several separate disease entities caused by mutations in 7TM 
receptors have been described. However, this number is likely to grow fast given to 
the fact, that over 160 7TM receptors are targeted in mice for homology with human 
diseases (SCHONEBERG et al. 2004). 
 
2. DISEASES CAUSED BY INACTIVATION MUTATIONS IN 7TM 
RECEPTORS 
The chances of mutational inactivation of the receptor are high. Amino acid 
substitution, deletion or insertion may cause loss or prematurely terminated 
transcription, improper protein folding or its inability to reach cell surface. 
Moreover, disruption of ligand binding pocket or receptor inability to bind with 
downstream signaling molecules, all result in loss of function phenotype (SPIEGEL 
2000; SPIEGEL, WEINSTEIN 2004).  
Diseases linked with inactivating mutations in 7TM receptors include: 
retinitis pigmentosa (RP) caused by mutations in rhodopsin; hypothyroidism and 
resistance to thyroid-stimulating hormone (TSH) caused by mutations in TSH 
receptor; nephrogenic diabetes insipidus (NDI) characterised by polyuria, polydipsia 
and hyposthenuria as a effect of mutations in vasopressin type 2 (V2) receptor 
(BARAK et al. 2001); Blomstrand chondrodysplasia in which mutations in 
parathyroid hormone/parathyroid hormone – related peptide (PTH/PTH-related 
peptide type 1) receptor; rare disease of familial hypocalciuric hypocalcaemia and 
potentially lethal neonatal severe hyperparathyroidism are linked with inactivating 
mutations in calcium-sensing receptor. Human red-hair color phenotype 
characterized by red hair, fair skin and poor ability to tan associated with loss of 
brown/black pigment eumelanin production, and susceptibility to development of 
skin cancers, have been linked with more than 60 variants of melanocortin type 1 
(MC1R) receptor (SANCHEZ-LAORDEN et al. 2007; TAO 2006). Interestingly, 
inactivating mutations of CCR5 chemokine receptor, especially CCR5∆32 are 
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associated with strong resistance to HIV infections, and slower progression of the 
disease (BALISTRERI et al. 2007).  
 
2.1 Rhodopsin mutations and retinitis pigmentosa 
A growing list of over 150 mutations, most of them missense or small in 
frame deletions, are primary causes of retinitis pigmentosa. Patients carrying this 
phenotypically and genetically diverse disease suffer from retinal dystrophy with 
symptoms ranging from night blindness to progressive loss of visual field 
(SCHONEBERG et al. 2004; TAO 2006).The first ever described mutation that causes 
this disease in humans was P23H substitution in rhodopsin. Mutated rhodopsin is 
retained in endoplasmic reticulum due to misfolding and aggregation. Although 
many single nucleotide mutations which causes retinitis pigmentosa can be found 
throughout the rhodopsin, cytoplasmatic part of the receptor and regions 
surrounding disulfide bridge connecting second extracellular loop with top of 
transmembrane three are more prone to hold retinitis pigmentosa mutations 
(STOJANOVIC, HWA 2002). The mechanism of retinal cells entering apoptotic 
pathway remains elusive, however, growing evidence suggest that aberrant 
formation of multimeric receptors complexes may contribute to this phenomena 
(ABDULAEV 2003). 
 
2.2 Leptin/Melanocortin circuit; melanocortin receptor and severe obesity 
Circulating leptin levels give the brain a reading of energy storage for the 
purposes of regulating appetite and metabolism. Leptin works by inhibiting the 
activity of neurons that contain neuropeptide Y (NPY) and agouti-related peptide 
(AgRP), and by increasing the activity of neurons expressing melanocyte-
stimulating hormone (MSH).  
Melanocortins are an important mediator of satiety. Leptin is produced in the 
adipocytes and mutations in the gene for the melanocortin receptors (MCRs) are 
linked to obesity in humans (TAO 2005). MC3R seems to exert its function in fat 
depository processes, rather than regulation of food intake. Inactivation of MC3R in 
mice results in elevated amount of fat mass while total body weight remains 
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unchanged (BUTLER et al. 2000; CHEN et al. 2000). Only recently first mutations of 
MC3R in obese patients were identified (LEE et al. 2002; RACHED et al. 2004; TAO, 
SEGALOFF 2004), confirming the importance of MC3R receptor in maintaining 
energy balance in the body. Heterozygous MC4 receptor mutations are found in 1–
6% of severe cases of human obesity. More than 50 mutations in MC4 receptor 
gene, many of which were identified as heterozygous missense mutations, linked to 
obesity have been described in adults with morbid obesity or children with early 
onset obesity (GOVAERTS et al. 2005). The exact mechanism of observed dominant-
negative effect of mutated MC4R is still far being clear, however recent reports 
suggest that altered sequence of MC4R may contribute to aberrant formation of 
multimeric complexes (BIEBERMANN et al. 2003). 
 
2.3 7TM receptors mutations and reproductive physiology 
Gonadothropin releasing hormone (GnRH) plays pivotal role in 
neuroendocrine regulation of reproduction. Hypogonadotropic hypogonadism occurs 
in patients with lack of GnRH receptor function. Characteristic for this disease is 
absence or decreased function of male testes or the female ovaries. Follitropin (FSH) 
receptor inefficiency is responsible for female infertility due to ovarian dysgenesis. 
At least 22 mutations in lutropin (LH) receptor responsible for production of 
testosterone have been reported to cause pseudohermaphroditis in males and 
hypergonadotropic hypogonadism, and primary amenorrhea in females (TAO 2006). 
 
2.4 Growth hormone releasing hormone receptors and dwarfism 
Growth hormone releasing hormone (GHRH) is synthesized and secreted by 
the arcuate nucleus of the hypothalamus. GHRH stimulates synthesis and secretion 
of growth hormone. Defective signaling in GHRH axis results in somatotroph 
hypoplasia and growth deficiency. GHRH receptor mutation was first identified in 
little mouse strain. Mutated murine GHRH receptor is unable to bind its ligand 
properly. In humans mutant receptors show aberrant signaling (TAO 2006). 
Inactivating mutations of growth hormone releasing hormone receptor lead to 
isolated growth hormone (GH) deficiency (LIN-SU, WAJNRAJCH 2002). At the same 
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time overexpression of GHRH was found to be an important factor in development 
of pituitary adenomas in mice (MAYO et al. 1988). 
 
3. DISEASES CAUSED BY ACTIVATING MUTATIONS IN 7TM 
RECEPTORS 
Gain of function mutations of 7TM receptors are in most cases missense 
mutations, however due to the fact that most of them are lethal during 
embryogenesis and thus undetectable, only 13% of diseases caused by mutated 7TM 
receptors are characterized by induction of agonist independent signaling. 
Constitutive activation of luteinizing hormone and thyrotropin receptors are cause of 
familial male precocious puberty characterized by accelerated sexual development at 
the age of 2 – 5 years. Familial hypocalcaemia is caused by calcium receptor 
hypersensivity to circulating Ca2+ and thus excessive hypercalcuria (SCHONEBERG et 
al. 2004; SPIEGEL, WEINSTEIN 2004).  
Since many agonists for 7TM receptors exhibit mitogenic activity, many 
somatic gain of function mutations in 7TMRs are linked to development of 
adenomas and malignant tumors. In approximately 80% of thyroid adenomas 
activating mutations in thyrotropin receptors are reported. Smoothened, a member of 
frizzled family of 7TMRs that signals through hedgehog pathway is supposed cause 
of basal cell carcinoma (SCHONEBERG et al. 2004). Tumorigenic activity has been 
demonstrated for constitutively active receptors encoded by Kaposi’s sarcoma 
associated virus and human cytomegalovirus (SODHI et al. 2004; VISCHER et al. 
2006) 
 
4. ABERRANT 7TM RECEPTORS EXPRESSION IN NEOPLASMS 
Alterations in expression of different 7TM receptors have been reported in 
numerous human both benign and malignant neoplasms. It has been showed that 
aberrant expression of gastric inhibitory polypeptide and luteinizing hormone 
receptors is a sufficient event to trigger hyperplastic growth of adrenogortical cells 
(MAZZUCO et al. 2007). Systematic study of data from microarray analysis of 
primary lung, breast, prostate, gastric and melanoma cancers has revealed that 
 
A. I. CYGANKIEWICZ 39
expression of multiple e.g., chemokine, PAR, neuropeptide, adenosine, purine and 
calcium receptors are significantly upregulated in human neoplasms (LI et al. 2005). 
Summary of latest findings on changes in 7TM receptors expression changes in 
various human neoplasms is presented in Tables 1a and 1b. 
 
Table 1a. Abberations in 7TM receptors expression in neoplastic cells 
 
Receptor Ligand Expression Neoplasm  Reference 
AXOR12 KiSS-1 peptide ? 
high grade 
epithelial 
ovarian cancer 
 HATA et al. 2007 
Cb2 cannabinoids ? 
acute 
myelogenous 
leukemia 
overexpressed 
in human 
myeloid 
leukemia cell 
lines 
JORDA et al. 
2004 
CRH-R 
corticotropin-
releasing 
hormone 
? corticotroph tumours  
DE KEYZER 
et al. 1998 
CysLT2R leukotriene C4 ? colorectal adenocarcinoma 
subsequent 
downregulation 
causes poor 
prognosis 
MAGNUSSON 
et al. 2007 
D-GPCR odorants ? malignant prostate 
upregulation 
correlated with 
advancement of 
tumor 
FUESSEL et 
al. 2006 
FZD7 Wnt proteins ? hepatic cancers 
subsequent 
activation of 
Wnt/beta 
catenin pathway 
MERLE et al. 
2005 
Ghrelin 1a ghrelin ? adenoid cystic carcinoma 
parallel 
overexpression  
of 1b isoform 
BARZON et 
al. 2005 
GnRH 
gonadotropin-
releasing 
hormone 
? multiple  EAVERI et al. 2004 
GPR30 estrogen ? breast cancer 
upregulation 
correlated with 
tumor size, 
invasiveness, 
Her2/neu 
expression 
FILARDO et 
al. 2006 
  ? infiltrating ductal carcinoma 
correlation in 
ER+ cells 
KUO et al. 
2007 
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Table 1b. Abberations in 7TM receptors expression in neoplastic cells (continued) 
 
Receptor Ligand Expression Neoplasm  Reference 
GPR48 orphan ? multiple 
downregulation  
of p27(Kip1) 
 is associated 
with increased 
tumor 
malignancy and 
poor prognosis 
GAO et al. 
2006 
GPR49 orphan ? colon, primary ovarian  
MCCLANAH
AN et al. 
2006 
GPR54 Kisspeptin ? bladder, thyroid  NICOLLE et al. 2007 
? pancreas in vitro study HUANG et al. 2007 GPR56 orphan 
? gliomas  SHASHIDHAR et al. 2005 
GPR87 lysophosphatidic acid ? 
lung squamous 
cell carcinoma  
GUGGER et 
al. 2008 
LPA2/3 lysophosphatidic acid ? colon 
in vitro study; 
LPA induced 
proliferation 
mediated by 
beta catenin 
pathway 
YANG et al. 
2005 
LPA2 lysophosphatidic acid ? 
invasive ductal 
carcinoma  
KITAYAMA 
et al. 2004 
Metastin KiSS-1 peptide ? thyroid papillary carcinoma  
RINGEL et 
al. 2002 
Orphan 
BTR orphan ? prostate  
PARMIGIANI 
et al. 2004 
colon, prostate, 
aggressive 
melanoma, 
invasive breast 
 ARORA et al. 2007 
PAR1 thrombin ? 
high grade 
endometrial 
cancer 
no expression in 
benign tumors 
GRANOVSKY
-GRISARU et 
al. 2006 
SCTR secretin ? pancreas 
dominant 
negative effect 
of truncated 
secretin receptor 
KORNER et 
al. 2005 
V3 vasopressin ? corticotroph tumors  
DE KEYZER 
et al. 1998 
5. COMMERCIAL POTENTIAL OF 7TM RECEPTORS 
7TM receptors are one of the most studied targets for present and future 
therapy targets. More than 30% of all drugs on the market are believed to exert their 
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clinical action through one of the 7TM receptors family members (HOPKINS, GROOM 
2002). About half of the commercially exploited 7TMRs are activated by 
polypeptide/protein ligands, further over 25% with biogenic amine ligands. But still 
less than 30% of 7TMRs which are identified in human genome are currently 
targeted by pharmacological therapies (LAGERSTROM, SCHIOTH 2008).  
7TMRs make a very good drug targets, however pharmacological profiling of still 
existing, orphan receptors and searching for new drug candidates for receptors with 
established natural ligands have forced scientists and pharmacological industry to 
come up with highly efficient systems able to efficiently screen 7TMRs of interest 
against vast compound libraries. The general strategy that enables resourceful 
characterization of orphan is termed “reverse pharmacology” approach. It employs 
studied receptor as a bait to fish out its ligand at first step, usually out of biologically 
active tissue or organ extracts (WILSON et al. 1998).  
Out of top 20 drug best sellers in the U.S. in 2003, 35% were 7TMR related, 
and have brought over 16 billion $ of income (SCHLYER, HORUK 2006). 
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